» Articles » PMID: 10584879

Expression and Subcellular Localization of Cyclin D1 Protein in Epithelial Ovarian Tumour Cells

Overview
Journal Br J Cancer
Specialty Oncology
Date 1999 Dec 10
PMID 10584879
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The expression of cyclin D1 protein in tumour sections from 81 patients with epithelial ovarian cancer was analysed using immunohistochemistry. The tumours that overexpressed cyclin D1 in more than 10% of neoplastic cells were considered positive. Thus overexpression of cyclin D1 was observed in 72/81 (89%) of the cases examined. Protein was detected in both the nucleus and the cytoplasm in 24/81 (30%) and localized exclusively in the cytoplasm in 48/81 (59%) of the tumours. Cyclin D1 was overexpressed in both borderline and invasive tumours. There was no association between protein overexpression and tumour stage and differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed. However, in tumours overexpressing cyclin D1 (n = 72), the proportion displaying exclusively cytoplasmic localization of protein was higher in those with serous compared with non-serous histology (P = 0.004, odds ratio 4.8, 95% confidence interval 1.4-19.1). Western analysis using a monoclonal antibody to cyclin D1 identified a 36 kDa protein in homogenates from seven tumours displaying cytoplasmic only and one tumour demonstrating both nuclear and cytoplasmic immunostaining. Using restriction fragment length polymorphism polymerase chain reaction and PCR-multiplex analysis, amplification of the cyclin D1 gene (CCND1 was detected in 1/29 of the tumours demonstrating overexpression of cyclin D1 protein. We conclude that deregulation of CCND1 expression leading to both cytoplasmic and nuclear protein localization is a frequent event in ovarian cancer and occurs mainly in the absence of gene amplification.

Citing Articles

The Clinicopathological Significance of the Cyclin D1/E1-Cyclin-Dependent Kinase (CDK2/4/6)-Retinoblastoma (RB1/pRB1) Pathway in Epithelial Ovarian Cancers.

Lashen A, Algethami M, Alqahtani S, Shoqafi A, Sheha A, Jeyapalan J Int J Mol Sci. 2024; 25(7).

PMID: 38612869 PMC: 11012085. DOI: 10.3390/ijms25074060.


Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives.

DallAcqua A, Bartoletti M, Masoudi-Khoram N, Sorio R, Puglisi F, Belletti B Cancers (Basel). 2021; 13(12).

PMID: 34204543 PMC: 8235237. DOI: 10.3390/cancers13123035.


Human La Protein: An RNA-Binding Protein Involved in Ovarian Cancer Development and Multidrug Resistance.

Huang X, Tang J Onco Targets Ther. 2020; 13:10721-10727.

PMID: 33132701 PMC: 7592153. DOI: 10.2147/OTT.S269983.


Knockdown of ALPK2 inhibits the development and progression of Ovarian Cancer.

Zhu X, Yan S, Xiao S, Xue M Cancer Cell Int. 2020; 20:267.

PMID: 32595416 PMC: 7313216. DOI: 10.1186/s12935-020-01347-z.


CyclinD1 promotes lymph node metastasis by inducing lymphangiogenesis in human ovarian carcinoma.

Li M, Zheng W, Wang C Int J Clin Exp Pathol. 2020; 11(7):3726-3731.

PMID: 31949756 PMC: 6962868.


References
1.
de Boer C, Loyson S, Kluin P, Kluin-Nelemans H, Schuuring E, van Krieken J . Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. Cancer Res. 1993; 53(18):4148-52. View

2.
Diehl J, Sherr C . A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol. 1997; 17(12):7362-74. PMC: 232592. DOI: 10.1128/MCB.17.12.7362. View

3.
. Non-surgical aspects of ovarian cancer. Lancet. 1994; 343(8893):335-40. View

4.
Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C . Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994; 54(7):1812-7. View

5.
Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M . Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res. 1994; 54(12):3107-10. View